From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes

Kyung Bo Kim, Craig M. Crews

Research output: Contribution to journalArticlepeer-review

124 Scopus citations

Abstract

Covering: 1992 to 2012 The initial enthusiasm following the discovery of a pharmacologically active natural product is often fleeting due to the poor prospects for its ultimate clinical application. Despite this, the ever-changing landscape of modern biology has a constant need for molecular probes that can aid in our understanding of biological processes. After its initial discovery by Bristol-Myers Squibb as a microbial anti-tumor natural product, epoxomicin was deemed unfit for development due to its peptide structure and potentially labile epoxyketone pharmacophore. Despite its drawbacks, epoxomicin’s pharmacophore was found to provide unprecedented selectivity for the proteasome. Epoxomicin also served as a scaffold for the generation of a synthetic tetrapeptide epoxyketone with improved activity, YU-101, which became the parent lead compound of carfilzomib (Kyprolis™), the recently approved therapeutic agent for multiple myeloma. In this era of rational drug design and high-throughput screening, the prospects for turning an active natural product into an approved therapy are often slim. However, by understanding the journey that began with the discovery of epoxomicin and ended with the successful use of carfilzomib in the clinic, we may find new insights into the keys for success in natural product-based drug discovery.

Original languageEnglish
Pages (from-to)600-604
Number of pages5
JournalNatural Product Reports
Volume30
Issue number5
DOIs
StatePublished - Apr 17 2013

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes'. Together they form a unique fingerprint.

Cite this